Skip to content

Vivani Medical VANI Additional Paid-In Capital

Additional Paid-In Capital at other companies

Eli Lilly logo
Eli LillyLLY
$6.92B+0.2%
Altimmune logo
AltimmuneALT
$961.24M+32.0%
Viking Therapeutics logo
Viking TherapeuticsVKTX
$1.51B+9.3%
Wave Life Sciences logo
Wave Life SciencesWVE
$237.43M+47.1%
Prime Medicine logo
Prime MedicinePRME
$1.01B+19.9%
Amylyx Pharmaceuticals, Inc. logo
Amylyx Pharmaceuticals, Inc.AMLX
$1.07B+26.3%

Other financials

Income statement

See full
Revenue-
Gross profit$130.0K
Operating income-$6.8M-4.0%
Net income-$6.8M-7.6%
EPS (diluted)-$0.08+27.3%

Balance sheet

See full
Cash & equivalents$19.0M+57.7%
Total debt$18.3M-3.5%
Total equity$19.1M+64.2%
Total assets$42.4M+19.5%

Cash flow

See full
Operating cash flow-$6.2M-20.0%
CapEx$3.0K-40.0%
Free cash flow-$6.2M-19.9%

Valuation

See full
Market cap$106.93M+40.0%
Enterprise value$106.17M+19.3%

Profitability

See full
Gross margin36.3%
Operating margin-1,004.9%
Net margin-994.1%
FCF margin-832.3%

Returns & leverage

See full
Return on equity-176.4%+175pp
Debt / equity-0.7×
Current ratio3.2×+0.8×

Where this comes from

Reported directly by Vivani Medical in its filing.

Tagged under the XBRL concept us-gaap:AdditionalPaidInCapital.

The official record: Vivani Medical’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Vivani Medical's additional paid-in capital.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Vivani Medical's additional paid-in capital?
Vivani Medical (VANI) reported additional paid-in capital of $174.36M in Q1 2026.
How has Vivani Medical's additional paid-in capital changed year-over-year?
Vivani Medical's additional paid-in capital increased by 24.7% year-over-year, from $139.8M to $174.36M.
What is the long-term trend for Vivani Medical's additional paid-in capital?
Over 5 years (2020 to 2025), Vivani Medical's additional paid-in capital has grown at a 27.2% compound annual growth rate (CAGR), from $49.31M to $164.23M.
What does additional paid-in capital mean?
Capital received from shareholders in excess of par value — the premium investors paid over the nominal value of shares at issuance, plus stock-based compensation effects.